Bayer leads Series B financing of Senti Bio

Tom Schmidtgen Tom Schmidtgen | 07.01.2021

Senti Bio receives 105 million US dollars. The financing round was led by Bayer.

Senti Biosciences is receiving a $105 million investment. Among the backers is Leaps by Bayer, the investment arm of Bayer AG. The San Francisco startup is working on new biological techniques to improve cell and gene therapies.

"We believe synthetic biology will become an important pillar in next-generation cell and gene therapies, and Senti Bio's leadership in developing and optimizing biological circuits fits perfectly with our goal of preventing and curing cancer and regenerating lost tissue function," said investor Juergen Eckhardt of Bayer. Senti Bio plans to start a preclinical study later this year.


Like it? Please spread the word:


Newsletter

Startups, stories and stats from the German startup ecosystem straight to your inbox. Subscribe with 2 clicks. Noice.

LinkedIn Connect

Take care, give care

Did this news inform or entertain you? Then we would be happy if you tell your network about it.

Share on Linkedin Share on Facebook Share on Xing

FYI: English edition available

Hello my friend, have you been stranded on the German edition of Startbase? At least your browser tells us, that you do not speak German - so maybe you would like to switch to the English edition instead?

Go to English edition

FYI: Deutsche Edition verfügbar

Hallo mein Freund, du befindest dich auf der Englischen Edition der Startbase und laut deinem Browser sprichst du eigentlich auch Deutsch. Magst du die Sprache wechseln?

Deutsche Edition öffnen

Similar posts